Pérez-Plasencia Carlos, López-Urrutia Eduardo, García-Castillo Verónica, Trujano-Camacho Samuel, López-Camarillo César, Campos-Parra Alma D
Laboratorio de Genómica Funcional, Unidad de Biomedicina, Facultad de Estudios Superiores Iztacala, UNAM, Tlalnepantla, Mexico.
Laboratorio de Genómica, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico.
Front Oncol. 2020 Aug 18;10:1037. doi: 10.3389/fonc.2020.01037. eCollection 2020.
The widespread dysregulation that characterizes cancer cells has been dissected and many regulation pathways common to multiple cancer types have been described in depth. Wnt/β-catenin signaling and autophagy are among these principal pathways, which contribute to tumor growth and resistance to anticancer therapies. Currently, several therapeutic strategies that target either Wnt/β-catenin signaling or autophagy are in various stages of development. Targeted therapies that block specific elements that participate in both pathways; are subject to studies as well as pre-clinical and early clinical trials. Strikingly, drugs designed for other diseases also impact these pathways, which is relevant since they are already FDA-approved and sometimes even routinely used in the clinic. The main focus of this mini-review is to highlight the importance of drug repositioning to inhibit the Wnt/β-catenin and autophagy pathways, with an emphasis on the interplay between them. The data we found strongly suggested that this field is worth further examination.
癌细胞广泛存在的失调现象已被深入剖析，多种癌症类型共有的许多调控途径也已得到详细描述。Wnt/β-连环蛋白信号传导和自噬就是这些主要途径，它们有助于肿瘤生长和对抗癌治疗产生抗性。目前，几种靶向Wnt/β-连环蛋白信号传导或自噬的治疗策略正处于不同的开发阶段。阻断参与这两种途径的特定元件的靶向疗法正在进行研究以及临床前和早期临床试验。引人注目的是，为其他疾病设计的药物也会影响这些途径，这很重要，因为它们已获得美国食品药品监督管理局（FDA）批准，有时甚至在临床上常规使用。本小型综述的主要重点是强调药物重新定位以抑制Wnt/β-连环蛋白和自噬途径的重要性，并着重探讨它们之间的相互作用。我们发现的数据有力地表明，这一领域值得进一步研究。
